[go: up one dir, main page]

ECSP10010158A - Derivados de piridina. - Google Patents

Derivados de piridina.

Info

Publication number
ECSP10010158A
ECSP10010158A EC2010010158A ECSP10010158A ECSP10010158A EC SP10010158 A ECSP10010158 A EC SP10010158A EC 2010010158 A EC2010010158 A EC 2010010158A EC SP10010158 A ECSP10010158 A EC SP10010158A EC SP10010158 A ECSP10010158 A EC SP10010158A
Authority
EC
Ecuador
Prior art keywords
piridine
derivatives
nephropathy
neuropathy
obesity
Prior art date
Application number
EC2010010158A
Other languages
English (en)
Inventor
Johannes Gleitz
Norbert Beier
Lars Thore Burgdorf
Christine Charon
Daniel Cravo
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ECSP10010158A publication Critical patent/ECSP10010158A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Nuevos compuestos heterocíclicos de la fórmula I en donde R1, R2, R3, R4 y D tienen los significados indicados en la reivindicación 1,son activadores de la glucoquinasa y se pueden usar para la prevención y/o el tratamiento de diabetes de tipo 1 y 2, obesidad, neuropatía y/o nefropatía.
EC2010010158A 2007-10-09 2010-05-05 Derivados de piridina. ECSP10010158A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07019691 2007-10-09
EP08001168 2008-01-23

Publications (1)

Publication Number Publication Date
ECSP10010158A true ECSP10010158A (es) 2010-06-29

Family

ID=39870670

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010158A ECSP10010158A (es) 2007-10-09 2010-05-05 Derivados de piridina.

Country Status (22)

Country Link
US (1) US8420642B2 (es)
EP (1) EP2195312B1 (es)
JP (1) JP5567481B2 (es)
KR (1) KR20100090250A (es)
CN (1) CN101821264A (es)
AR (1) AR068748A1 (es)
AU (1) AU2008310097B2 (es)
BR (1) BRPI0818658A2 (es)
CA (1) CA2701806A1 (es)
CY (1) CY1113767T1 (es)
DK (1) DK2195312T3 (es)
EA (1) EA201000561A1 (es)
EC (1) ECSP10010158A (es)
ES (1) ES2399469T3 (es)
HR (1) HRP20120948T1 (es)
IL (1) IL204746A0 (es)
MX (1) MX2010003759A (es)
NZ (1) NZ585236A (es)
PL (1) PL2195312T3 (es)
PT (1) PT2195312E (es)
SI (1) SI2195312T1 (es)
WO (1) WO2009046784A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2699718C (en) 2007-09-21 2014-05-27 Array Biopharma Inc. Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CN105176930B (zh) 2010-03-31 2021-05-04 斯克里普斯研究所 重编程细胞
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JPWO2012121314A1 (ja) 2011-03-09 2014-07-17 第一三共株式会社 ジピリジルアミン誘導体
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104230892B (zh) * 2011-11-09 2016-12-07 福建海西新药创制有限公司 一组提高激酶活性的化合物及其应用
JP5343177B1 (ja) 2012-02-28 2013-11-13 アステラス製薬株式会社 含窒素芳香族へテロ環化合物
TW201341367A (zh) 2012-03-16 2013-10-16 Axikin Pharmaceuticals Inc ３，５－二胺基吡唑激酶抑制劑
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
CN103664759A (zh) * 2013-12-06 2014-03-26 常熟市联创化学有限公司 一种3-羟基-2-硝基吡啶的制备方法
SG11201705088VA (en) 2014-12-23 2017-07-28 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
CN107635981B (zh) 2015-02-17 2020-08-04 中国科学院广州生物医药与健康研究院 用于诱导白色脂肪组织褐变的化合物和方法
US10968185B2 (en) * 2015-04-07 2021-04-06 Ela Pharma Ltd. Substituted thiazoles for preventing and/or treating cell or tissue necrosis
WO2016164703A1 (en) * 2015-04-09 2016-10-13 Eisai R & D Management Co., Ltd. Fgfr4 inhibitors
JP2022500499A (ja) 2018-09-07 2022-01-04 ピク セラピューティクス， インコーポレイテッド Ｅｉｆ４ｅ阻害剤およびその使用
CN110568100B (zh) * 2019-09-12 2022-05-31 江西金水宝制药有限公司 一种米格列奈钙r-异构体的检测方法
MX2022010944A (es) 2020-03-03 2022-11-09 Pic Therapeutics Inc Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos.
CN114685491B (zh) * 2020-12-31 2024-01-12 清华大学 吡啶-2-胺衍生物及其药物组合物和用途
CN118019739A (zh) 2021-08-25 2024-05-10 皮克医疗公司 Eif4e抑制剂及其用途
WO2023028235A1 (en) 2021-08-25 2023-03-02 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0178035B1 (en) 1984-05-12 1990-01-03 FISONS plc Anti-inflammatory 1,n-diarylpyrazol-3-amines, compositions containing them and processes for their preparation
CA1305478C (en) * 1986-11-06 1992-07-21 Margaret H. Sherlock Naphthyridine and pyridopyrazine compounds and pharmaceutical usage thereof
JPH07285962A (ja) 1994-04-20 1995-10-31 Nissan Chem Ind Ltd ピリジンカルボン酸アミド誘導体
EP0790057B1 (en) 1994-11-29 2002-06-05 Hisamitsu Pharmaceutical Co., Inc. Antibacterial or bactericide comprising 2-aminothiazole derivative and salts thereof
WO1996018616A1 (en) 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
WO1996018617A1 (en) 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
EA200200351A1 (ru) 1999-09-10 2002-10-31 Мерк Энд Ко., Инк. Ингибиторы тирозинкиназы
EP1289960A2 (en) 2000-06-15 2003-03-12 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists
CA2410945A1 (en) * 2000-07-04 2002-01-10 Neurosearch A/S Aryl and heteroaryl diazabicycloalkanes, their preparation and use
US20020173524A1 (en) 2000-10-11 2002-11-21 Tularik Inc. Modulation of CCR4 function
HUP0303538A2 (hu) 2000-12-21 2005-02-28 Bristol-Myers Squibb Co. Tirozin kinázok Tec családjának tiazolil-vegyület inhibitorai és ezeket tartalmazó gyógyszerkészítmények
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
WO2003027085A2 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
EP1336607A1 (en) 2002-02-19 2003-08-20 Novo Nordisk A/S Amide derivatives as glucokinase activators
US20030171411A1 (en) * 2001-12-21 2003-09-11 Kodra Janos Tibor Amide derivatives as therapeutic agents
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
AU2004212490B2 (en) 2003-02-10 2008-05-15 Amgen Inc. Vanilloid receptor ligands and their use in treatments
JP4432901B2 (ja) * 2003-02-26 2010-03-17 萬有製薬株式会社 ヘテロアリールカルバモイルベンゼン誘導体
JP2007516227A (ja) 2003-05-16 2007-06-21 アンビット バイオサイエンシス コーポレーション ピロール化合物およびその使用
AU2004268112A1 (en) * 2003-09-02 2005-03-10 Merck & Co., Inc. Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5
WO2005040112A1 (en) * 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
JPWO2005090332A1 (ja) * 2004-03-23 2008-01-31 萬有製薬株式会社 置換キナゾリン又はピリドピリミジン誘導体
US20050227989A1 (en) 2004-04-13 2005-10-13 Icagen, Inc. Polycyclic thiazoles as potassium ion channel modulators
US20060019967A1 (en) 2004-07-21 2006-01-26 Su-Ying Wu SARS CoV main protease inhibitors
CA2579002C (en) 2004-09-02 2012-11-27 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
JP2008527043A (ja) 2005-01-19 2008-07-24 ブリストル−マイヤーズ スクイブ カンパニー 血栓塞栓障害治療用のｐ２ｙ１受容体阻害剤としての２−フェノキシ−ｎ−（１，３，４−チアジアゾール−２−イル）ピリジン−３−アミン誘導体および関連化合物
MX2007011512A (es) 2005-03-18 2007-12-07 Univ California Compuestos que tienen actividad para corregir procesamiento de cftr-mutante y usos de los mismos.
JP5075624B2 (ja) 2005-04-28 2012-11-21 田辺三菱製薬株式会社 シアノピリジン誘導体及びその医薬としての用途
UA92746C2 (en) * 2005-05-09 2010-12-10 Акилайон Фармасьютикалз, Инк. Thiazole compounds and methods of use
JP4651714B2 (ja) * 2005-07-09 2011-03-16 アストラゼネカ アクチボラグ 糖尿病の治療においてｇｌｋ活性化剤として使用するためのヘテロアリールベンズアミド誘導体
KR20080034436A (ko) 2005-07-21 2008-04-21 베타게논 에이비 암 치료에 사용되는 티아졸 유도체 및 유사체
JP2009503073A (ja) 2005-08-02 2009-01-29 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての５−置換チアゾール−２−イルアミノ化合物および組成物
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
NZ567858A (en) * 2005-11-01 2011-08-26 Array Biopharma Inc Pyridine compounds useful as Glucokinase activators
WO2007051846A1 (en) * 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
CN101437512A (zh) 2006-01-27 2009-05-20 阿雷生物药品公司 葡萄糖激酶活化剂
CN101437816B (zh) 2006-03-24 2013-08-14 阿雷生物药品公司 作为葡萄糖激酶活性剂的2-氨基吡啶类似物
WO2008091770A1 (en) * 2007-01-24 2008-07-31 Array Biopharma Inc. 2-aminopyridine derivatives as glucokinase activators
JP2010520887A (ja) * 2007-03-09 2010-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド 蛋白キナーゼの阻害剤として有用なアミノピリジン
US8362037B2 (en) * 2007-03-23 2013-01-29 Array Biopharma, Inc. 2-aminopyridine analogs as glucokinase activators
UA99459C2 (en) * 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer

Also Published As

Publication number Publication date
US8420642B2 (en) 2013-04-16
EP2195312A1 (en) 2010-06-16
AU2008310097A1 (en) 2009-04-16
KR20100090250A (ko) 2010-08-13
HRP20120948T1 (hr) 2012-12-31
ES2399469T3 (es) 2013-04-01
BRPI0818658A2 (pt) 2015-04-14
MX2010003759A (es) 2010-04-21
JP5567481B2 (ja) 2014-08-06
DK2195312T3 (da) 2013-01-02
NZ585236A (en) 2012-03-30
WO2009046784A1 (en) 2009-04-16
IL204746A0 (en) 2010-11-30
AU2008310097B2 (en) 2013-05-16
AR068748A1 (es) 2009-12-02
CA2701806A1 (en) 2009-04-16
CN101821264A (zh) 2010-09-01
EA201000561A1 (ru) 2010-10-29
PT2195312E (pt) 2013-02-20
JP2010540667A (ja) 2010-12-24
CY1113767T1 (el) 2016-07-27
EP2195312B1 (en) 2012-11-21
PL2195312T3 (pl) 2013-04-30
SI2195312T1 (sl) 2013-01-31
US20100216794A1 (en) 2010-08-26

Similar Documents

Publication Publication Date Title
ECSP10010158A (es) Derivados de piridina.
ECSP10010163A (es) Derivados de n-(pirazol-3-il)-benzamida
EA201001358A1 (ru) Активаторы глюкокиназы
CY1112919T1 (el) Παραγωγα β-αμινοξεων για τη θεραπευτικη αντιμετωπιση του διαβητη
CL2008001017A1 (es) Compuestos derivados de indol, activadores de glucoquinasa; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de diabetes u obesidad.
CL2008003847A1 (es) Compuestos derivados de 6-fenilpirazin-2-carboxamida y 6-fenilpirazin-2-carbotioamida, inhibidores de dgat-1; composicion farmaceutica; y su uso en el tratamiento de la diabetes mellitus y obesidad.
CY1112921T1 (el) Ενεργοποιητες γλυκοκινασης πυρρολιδινονης
DE502007004290D1 (de) Carbazol-derivate für organische elektrolumineszenzvorrichtungen
CO6270257A2 (es) Derivados de piridazinona
UY28005A1 (es) Indol -3-carboxamidas como activadores de glucoquinasa (gk)
CY1109322T1 (el) Παραγωγα προλινης και η χρηση τους ως αναστολεις διπεπτιδυλικης πεπτιδασης iv
EP2468725A4 (en) AROMATIC AMINE DERIVATIVES AND ORGANIC ELECTROLUMINESCENE ELEMENTS THEREWITH
CL2008000915A1 (es) Compuestos triciclicos moduladores de 11beta-hidroxiesteroidedeshidrogenasa tipo 1; y uso en el tratamiento, prevencion y/o profilaxis de enfermedades tales como sindrome metabolico, resistencia a la insulina, dislipidemia, hipertension y obesidad.
MX2008011123A (es) Benzotiazoles que tienen actividad de receptor h3 de histamina.
CL2008002871A1 (es) Compuestos derivados de oxadiazol-bencimidazol; composicion farmaceutica que los contiene y su uso como inhibidores de dgt1 para el tratamiento de la tolerancia deteriorada a la glucosa, diabetes tipo 2 y obesidad.
ECSP088164A (es) Derivados de heteroaril benzamida para uso como activadores de glk en el tratamiento de la diabetes
EA201001367A1 (ru) Производные карбоксамид-гетероарила для лечения диабета
CL2007002757A1 (es) Compuestos derivados de 1,2,4-triazina sustituida; composicion farmaceutica; y uso en el tratamiento o prevencion del reflujo gastroesofagico y ansiedad.
CY1111556T1 (el) Παραγωγα 2-βενζυλοπυριδαζινονης ως αναστολεις μετ-κινασης
ATE514765T1 (de) Azeotropartige zusammensetzungen mit 1,1,1,2,3,3- hexafluor-3-methoxypropan und 1-brompropan
ATE478054T1 (de) Benzimidazolderivate
DOP2010000102A (es) Benzotiazoles como moduladores del receptor de grelina
ATE488235T1 (de) Neue 2-amino-benzimidazolderivate und ihre verwendung als modulatoren calciumaktivierter kaliumkanäle mit geringer leitfähigkeit
UY30033A1 (es) Uso de derivados heterociclicos benzo _fusionados de sulfamida para el tratamiento de la obesidad
TW200700358A (en) Organic compounds